Opinions on Serina and Enable's New Collaboration to Create SER-252 for Parkinson Disease.

Published Date: 02 Jun 2024

The development plans for SER-252, an investigational apomorphine therapy for advanced Parkinson disease, were discussed by Randall Moreadith, MD, PhD, chief development officer of Serina Therapeutics, and Mike Hooven, chairman and CEO of Enable Injections.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

New surgical method shows promising results for cervical cancer treatment

2.

Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth

3.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

4.

Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer

5.

Can Prior Authorization Be Better With Artificial Intelligence?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot